Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model.

Igarashi K, Kawaguchi K, Kiyuna T, Miyake K, Miyake M, Li Y, Nelson SD, Dry SM, Singh AS, Elliott IA, Russell TA, Eckardt MA, Yamamoto N, Hayashi K, Kimura H, Miwa S, Tsuchiya H, Eilber FC, Hoffman RM.

Oncotarget. 2017 Dec 4;9(8):7774-7781. doi: 10.18632/oncotarget.22892. eCollection 2018 Jan 30.

2.

Methotrexate Free Chemotherapy and Limb Salvage Surgery for Paediatric Osteosarcoma in India.

Sukumaran RK, Rajeshwari B, Sugath S, Chellappan SG, Thankamony P, Parukuttyamma K.

Indian J Orthop. 2018 Jan-Feb;52(1):58-64. doi: 10.4103/ortho.IJOrtho_195_17.

3.

Analysis of imaging characteristics of primary malignant bone tumors in children.

Sun Y, Liu X, Pan S, Deng C, Li X, Guo Q.

Oncol Lett. 2017 Nov;14(5):5801-5810. doi: 10.3892/ol.2017.6939. Epub 2017 Sep 14.

4.

A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatinum-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology.

Igarashi K, Murakami T, Kawaguchi K, Kiyuna T, Miyake K, Zhang Y, Nelson SD, Dry SM, Li Y, Yanagawa J, Russell TA, Singh AS, Tsuchiya H, Elliott I, Eilber FC, Hoffman RM.

Oncotarget. 2017 Jul 8;8(37):62111-62119. doi: 10.18632/oncotarget.19095. eCollection 2017 Sep 22.

5.

Value of diffusion-weighted imaging for evaluating chemotherapy response in osteosarcoma: A meta-analysis.

Kubo T, Furuta T, Johan MP, Ochi M, Adachi N.

Mol Clin Oncol. 2017 Jul;7(1):88-92. doi: 10.3892/mco.2017.1273. Epub 2017 May 29.

6.

18F-FDG Uptake During Early Adjuvant Chemotherapy Predicts Histologic Response in Pediatric and Young Adult Patients with Osteosarcoma.

Davis JC, Daw NC, Navid F, Billups CA, Wu J, Bahrami A, Jenkins JJ, Snyder SE, Reddick WE, Santana VM, McCarville MB, Guo J, Shulkin BL.

J Nucl Med. 2018 Jan;59(1):25-30. doi: 10.2967/jnumed.117.190595. Epub 2017 Jun 13.

PMID:
28611244
7.

Effectiveness of multi-drug regimen chemotherapy treatment in osteosarcoma patients: a network meta-analysis of randomized controlled trials.

Wang X, Zheng H, Shou T, Tang C, Miao K, Wang P.

J Orthop Surg Res. 2017 Mar 29;12(1):52. doi: 10.1186/s13018-017-0544-9.

9.

Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients.

Hattinger CM, Vella S, Tavanti E, Fanelli M, Picci P, Serra M.

Pharmacogenomics. 2016 Dec;17(18):2097-2114. Epub 2016 Nov 24. Review.

10.

The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas.

Palmerini E, Colangeli M, Nanni C, Fanti S, Marchesi E, Paioli A, Picci P, Cambioli S, Donati D, Cevolani L, De Paolis M, Gambarotti M, Ferrari S.

Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):215-223. doi: 10.1007/s00259-016-3509-z. Epub 2016 Sep 20.

11.

Emerging roles for long noncoding RNAs in skeletal biology and disease.

Huynh NP, Anderson BA, Guilak F, McAlinden A.

Connect Tissue Res. 2017 Jan;58(1):116-141. doi: 10.1080/03008207.2016.1194406. Epub 2016 Jun 2. Review.

12.

Assessing the Prognostic Significance of Histologic Response in Osteosarcoma: A Comparison of Outcomes on CCG-782 and INT0133-A Report From the Children's Oncology Group Bone Tumor Committee.

Bishop MW, Chang YC, Krailo MD, Meyers PA, Provisor AJ, Schwartz CL, Marina NM, Teot LA, Gebhardt MC, Gorlick R, Janeway KA, Chou AJ.

Pediatr Blood Cancer. 2016 Oct;63(10):1737-43. doi: 10.1002/pbc.26034. Epub 2016 Apr 29.

13.

Analysis of Prognostic Factors in High-Grade Osteosarcoma of the Extremities in Children: A 15-Year Single-Institution Experience.

Vasquez L, Tarrillo F, Oscanoa M, Maza I, Geronimo J, Paredes G, Silva JM, Sialer L.

Front Oncol. 2016 Feb 2;6:22. doi: 10.3389/fonc.2016.00022. eCollection 2016.

14.

The Current and Future Therapies for Human Osteosarcoma.

Lamplot JD, Denduluri S, Qin J, Li R, Liu X, Zhang H, Chen X, Wang N, Pratt A, Shui W, Luo X, Nan G, Deng ZL, Luo J, Haydon RC, He TC, Luu HH.

Curr Cancer Ther Rev. 2013 Feb;9(1):55-77.

15.

The efficacy of high-dose versus moderate-dose chemotherapy in treating osteosarcoma: a systematic review and meta-analysis.

Wang WG, Wan C, Liao GJ.

Int J Clin Exp Med. 2015 Sep 15;8(9):15967-74. eCollection 2015.

16.

Bone mineral density change during adjuvant chemotherapy in pediatric osteosarcoma.

Ahn JH, Cho WH, Lee JA, Kim DH, Seo JH, Lim JS.

Ann Pediatr Endocrinol Metab. 2015 Sep;20(3):150-4. doi: 10.6065/apem.2015.20.3.150. Epub 2015 Sep 30.

17.

Osteosarcoma: Current Treatment and a Collaborative Pathway to Success.

Isakoff MS, Bielack SS, Meltzer P, Gorlick R.

J Clin Oncol. 2015 Sep 20;33(27):3029-35. doi: 10.1200/JCO.2014.59.4895. Epub 2015 Aug 24. Review.

18.

Fertility following treatment of high-grade malignant bone and soft tissue tumors in young adults.

Hoshi M, Takami M, Ieguchi M, Aono M, Takada J, Oebisu N, Iwai T, Nakamura H.

Mol Clin Oncol. 2015 Mar;3(2):367-374. Epub 2014 Dec 3.

19.

Adenovirus-delivered PDCD5 counteracts adriamycin resistance of osteosarcoma cells through enhancing apoptosis and inhibiting Pgp.

Zhao H, Peng C, Ruan G, Zhou J, Li Y, Hai Y.

Int J Clin Exp Med. 2014 Dec 15;7(12):5429-36. eCollection 2014.

20.

CORR Insights(®): survival, recurrence, and function after epiphyseal preservation and allograft reconstruction in osteosarcoma of the knee.

Fabbri N.

Clin Orthop Relat Res. 2015 May;473(5):1797-801. doi: 10.1007/s11999-014-4121-9. Epub 2015 Jan 8. No abstract available.

Supplemental Content

Support Center